Mark Dolman
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- SARS-CoV-2 detection and testing
-
- Antibiotic Use and Resistance
Papers in
-
- COVID-19 Clinical Research Studies 6
- SARS-CoV-2 detection and testing 1
- Partner nations
- United KingdomVietnamNepal
In The Last Decade
Mark Dolman
7 papers receiving 1.7k citations
Mark Dolman's Hit Papers
Peers
Comparison fields: 5 of 86
- Infectious Diseases 1.4k
- Applied Microbiology and Biotechnology 35
- Internal Medicine 27
- Modeling and Simulation 22
- Statistics and Probability 46
Countries citing papers authored by Mark Dolman
This map shows the geographic impact of Mark Dolman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Dolman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Dolman more than expected).
Fields of papers citing papers by Mark Dolman
This network shows the impact of papers produced by Mark Dolman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Dolman. The network helps show where Mark Dolman may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 5 | 2021 | 213 | |
| 6 | 2021 | 173 | |
| 7 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
About Mark Dolman
Mark Dolman is a scholar working on Infectious Diseases, Nuclear Energy and Engineering, Waste Management and Disposal, Organic Chemistry and Surgery, having authored 7 papers that have together received 1.8k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (6 papers) and SARS-CoV-2 detection and testing (1 paper). The work is most often cited by research in Infectious Diseases (1.4k citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (27 citations), Modeling and Simulation (22 citations) and Statistics and Probability (46 citations). Mark Dolman has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Their work appears in journals such as The Lancet and EClinicalMedicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.